SEBIVO (telbivudine) - Advisories, Warnings & Recalls

From Health Canada:
Novartis Pharmaceuticals Canada Inc., in consultation with Health Canada, would like to inform you of an increased risk of peripheral neuropathy observed in chronic hepatitis B patients treated with telbivudine (SEBIVO®) in combination with peginterferon alfa-2a (Pegasys®), compared to the interferon or telbivudine alone, during a controlled pilot clinical trial. An increased risk cannot be ruled out for treatments combining telbivudine with other interferon products (pegylated or standard).
For health care professionals
For the public